The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The potential economic impact of the 21-gene recurrence score–guided chemotherapy in a population-based cohort with node-negative and node-positive early-stage breast cancer.
N. W. Lamond
No relevant relationships to disclose
C. Skedgel
No relevant relationships to disclose
D. Rayson
No relevant relationships to disclose
L. Lethbridge
No relevant relationships to disclose
T. Younis
No relevant relationships to disclose